FATE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.695 USD | +7.10% |
|
+4.97% | -1.20% |
| Sales 2024 * | 5.82M 7.93M | Sales 2025 * | 5.39M 7.34M | Capitalization | 419M 571M |
|---|---|---|---|---|---|
| Net income 2024 * | -201M -274M | Net income 2025 * | -224M -305M | EV / Sales 2024 * | 32.6 x |
| Net cash position 2024 * | 229M 312M | Net cash position 2025 * | 153M 208M | EV / Sales 2025 * | 49.4 x |
| P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-2.06
x | Employees | 181 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Fate Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +7.10% | ||
| 1 week | +4.97% | ||
| Current month | +0.41% | ||
| 1 month | -9.88% | ||
| 3 months | -52.26% | ||
| 6 months | +39.43% | ||
| Current year | -1.20% |
1 week
3.34
3.72
1 month
3.344.54
Current year
3.348.83
1 year
1.638.83
3 years
1.6397.43
5 years
1.63121.16
10 years
1.46121.16
| Managers | Title | Age | Since |
|---|---|---|---|
J. Wolchko
FOU | Founder | 53 | 07-04-26 |
Edward Dulac
DFI | Director of Finance/CFO | 49 | 20-08-16 |
| Chairman | 75 | 11-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Epstein
BRD | Director/Board Member | 58 | 14-03-16 |
Robert Hershberg
BRD | Director/Board Member | 61 | 20-04-30 |
Tim Coughlin
BRD | Director/Board Member | 57 | 13-07-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.95% | 0 M€ | -.--% | - | |
| 2.10% | 1 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 3.68 | +6.67% | 3,629,455 |
| 24-05-30 | 3.45 | +0.58% | 1,508,044 |
| 24-05-29 | 3.43 | -3.11% | 2,907,515 |
| 24-05-28 | 3.54 | +0.57% | 1,699,730 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Calendar
2024-06-05
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
3.68
USD
Average target price
6.643
USD
Spread / Average Target
+80.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.20% | 419M | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- FATE Stock
